Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01678911 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Gralise® for Chronic Pelvic Pain
A Phase 4 study, sponsored by Shirley Ryan AbilityLab.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01678911 is a Phase 4 study that was terminated before completion, run by Shirley Ryan AbilityLab. The registered enrollment target is 11 participants.
The verdict
NCT01678911, a Phase 4 study, was terminated before completion, sponsored by Shirley Ryan AbilityLab.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study is done to investigate the pain relieving effects of the study drug Gralise (a novel long acting gabapentinoid) for people who experience chronic pelvic pain. Subjects with Irritable Bowel Syndrome, Interstitial Cystitis, Ulcerative Colitis, and Prostatitis will be recruited. The purpose of this research is to look at how the study drug can be used to benefit people who experience this type of pain. This is a phase IV study done to study the safety and effectiveness of the drug. At this point the drug has been approved by the Food and Drug Administration and has been reported to be well tolerated and effective in the treatment of various chronic pain conditions, particularly in neuropathic pain. About 36 subjects will take part in this study.
Interventions
- DRUG Gralise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01678911
The ClinicalTrials.gov registry entry for NCT01678911 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shirley Ryan AbilityLab, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gralise is the first listed.
NCT01678911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01678911 about?
NCT01678911 is a clinical study titled "Efficacy of Gralise® for Chronic Pelvic Pain". This study is done to investigate the pain relieving effects of the study drug Gralise (a novel long acting gabapentinoid) for people who experience chronic pelvic pain. Subjects with Irritable Bowel Syndrome, Interstitial Cystitis, Ulcerative Colitis, and Prostatitis will be recruited. The purpose ...
What is the current status of trial NCT01678911?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2012-08. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01678911?
The interventions under investigation include: Gralise (DRUG).
Who is sponsoring clinical trial NCT01678911?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.